» Articles » PMID: 16123586

Poly(ADP-ribose) Polymerase (PARP-1) in Homologous Recombination and As a Target for Cancer Therapy

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2005 Aug 27
PMID 16123586
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Poly(ADP-ribose) polymerase (PARP-1) binds to DNA breaks to facilitate DNA repair. However, the role of PARP-1 in DNA repair appears to not be critical since PARP-1 knockout mice are viable, fertile and do not develop early onset tumors. Cells isolated from these mice show an increased level of homologous recombination. There is an intricate link between homologous recombination and PARP-1 and a possible role for PARP-1 in DNA double-strand break repair. Although PARP-1 appears not to be required for homologous recombination itself, it regulates the process through its involvement in the repair of DNA single-strand breaks (SSBs). SSBs persisting into the S phase of the cell cycle collapse replication forks, triggering homologous recombination for replication restart. We discuss the recent discoveries on the use of PARP-1 inhibitors as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.

Citing Articles

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer.

Matthews B, Wong-Brown M, Liu D, Yee C, Dickson K, Schneider J Mol Ther Oncol. 2025; 32(4):200911.

PMID: 39802157 PMC: 11719850. DOI: 10.1016/j.omton.2024.200911.


Discovery of novel PARP1/NRP1 dual-targeting inhibitors with strong antitumor potency.

Liu J, Geng Y, Jiang S, Guan L, Gao J, Niu M Front Pharmacol. 2024; 15:1454957.

PMID: 39679370 PMC: 11637875. DOI: 10.3389/fphar.2024.1454957.


Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.

Luserna di Rora A, Jandoubi M, Padella A, Ferrari A, Marranci A, Mazzotti C J Transl Med. 2024; 22(1):1062.

PMID: 39587643 PMC: 11590640. DOI: 10.1186/s12967-024-05838-9.


Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.

Reshkin S, Cardone R, Koltai T Cells. 2024; 13(7.

PMID: 38607041 PMC: 11011857. DOI: 10.3390/cells13070602.


Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.

Zhu L, Xu R, Yang L, Shi W, Zhang Y, Liu J Front Genet. 2023; 14:1172108.

PMID: 37636270 PMC: 10448395. DOI: 10.3389/fgene.2023.1172108.